Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors

Clinical trial NCT04721015 · ACTIVE_NOT_RECRUITING

Trial details

NCT number

NCT04721015

Sponsor

AbbVie

Status

ACTIVE_NOT_RECRUITING

Phase

Phase 1

Study type

INTERVENTIONAL

Start date

2021-02-23

Primary completion

2026-02-01

Enrollment

81

View on ClinicalTrials.gov